ClinicalTrials.gg

TargetBeta

GPC3

glypican 3 · also OCI-5, SGBS, SGBS1, SGB · Glypicans

10 programs in company-led studies act on GPC3, from 10 companies: 1 in phase 3. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (6 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
Anti-GPC3/Anti-4-1BB Bispecific Antibody BGB-B2033ruleBeOne Medicinesphase 333 runningTNFRSF9NCIt
GPC3-targeted Plasmid DNA Vaccine NWRD06ruleNewish Biotech (Wuxi)phase 222 running–NCIt
Actinium Ac 225 GPC3-targeted Peptide RYZ801Bristol-Myers Squibbphase 211 running–a judged reading
Anti-GPC3 T Cell-engaging Antibody AZD9793AstraZenecaphase 211 runningCD3E, CD8Aa judged reading
codrituzumabHoffmann-La Rochephase 230 running–a judged reading
ACE723ruleAcepodia Biotechphase 111 running–the studies' text
Actinium Ac 225 GPC3-targeted Antibody Conjugate BAY 3547926ruleBayerphase 111 running–NCIt
Anti-GPC3 Antibody-drug Conjugate ABBV-324AbbViephase 111 running–a judged reading
Anti-GPC3 Antibody-drug Conjugate ZW251ruleZymeworksphase 111 running–NCIt
TQB6426ruleSino Biopharmaceuticalphase 111 running–the studies' text

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.